Detalhe da pesquisa
1.
LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma.
Cell
; 185(8): 1373-1388.e20, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35381199
2.
Coupled scRNA-Seq and Intracellular Protein Activity Reveal an Immunosuppressive Role of TREM2 in Cancer.
Cell
; 182(4): 872-885.e19, 2020 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32783915
3.
Single-cell immunology: Past, present, and future.
Immunity
; 55(3): 393-404, 2022 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263567
4.
Multi-tissue single-cell analysis deconstructs the complex programs of mouse natural killer and type 1 innate lymphoid cells in tissues and circulation.
Immunity
; 54(6): 1320-1337.e4, 2021 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33945787
5.
Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols.
Nat Cancer
; 5(5): 742-759, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38429414
6.
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
Sci Immunol
; 8(81): eadd8005, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36867679
7.
Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary.
Cancer Discov
; 13(12): 2610-2631, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37756565
8.
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Nat Cancer
; 3(11): 1336-1350, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36302895
9.
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Nat Cancer
; 3(11): 1404, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376510